(Reuters) - SCO Capital Partners LLC owns 13.4 percent of the biotechnology company's outstanding common stock as of May 3, 2007 according to a regulatory filing. On Tuesday, Genzyme said it had offered to buy Bioenvision for $5.60 a share or about a total of $345 million in cash. The deal would give Genzyme exclusive rights to clofarabine, a cancer treatment for children.
Read more at Reuters.com Mergers News
Read more at Reuters.com Mergers News
No comments:
Post a Comment